- Home
- PROF vs GNLX Comparison
PROF vs GNLX Comparison
Compare PROF & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROF
- GNLX
- Stock Information
- Founded
- PROF N/A
- GNLX 2001
- Country
- PROF Canada
- GNLX United States
- Employees
- PROF N/A
- GNLX N/A
- Industry
- PROF Medical/Dental Instruments
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- PROF Health Care
- GNLX Health Care
- Exchange
- PROF Nasdaq
- GNLX Nasdaq
- Market Cap
- PROF 201.2M
- GNLX 184.4M
- IPO Year
- PROF N/A
- GNLX 2023
- Fundamental
- Price
- PROF $7.48
- GNLX $4.81
- Analyst Decision
- PROF Strong Buy
- GNLX Strong Buy
- Analyst Count
- PROF 2
- GNLX 4
- Target Price
- PROF $11.40
- GNLX $18.25
- AVG Volume (30 Days)
- PROF 102.1K
- GNLX 331.4K
- Earning Date
- PROF 03-06-2025
- GNLX 03-31-2025
- Dividend Yield
- PROF N/A
- GNLX N/A
- EPS Growth
- PROF N/A
- GNLX N/A
- EPS
- PROF N/A
- GNLX N/A
- Revenue
- PROF $8,984,000.00
- GNLX $8,000.00
- Revenue This Year
- PROF $56.56
- GNLX N/A
- Revenue Next Year
- PROF $151.33
- GNLX N/A
- P/E Ratio
- PROF N/A
- GNLX N/A
- Revenue Growth
- PROF 39.35
- GNLX N/A
- 52 Week Low
- PROF $5.63
- GNLX $1.60
- 52 Week High
- PROF $11.42
- GNLX $8.67
- Technical
- Relative Strength Index (RSI)
- PROF 65.75
- GNLX 58.52
- Support Level
- PROF $5.63
- GNLX $4.62
- Resistance Level
- PROF $6.36
- GNLX $5.76
- Average True Range (ATR)
- PROF 0.36
- GNLX 0.57
- MACD
- PROF 0.18
- GNLX -0.03
- Stochastic Oscillator
- PROF 87.26
- GNLX 59.96
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.